Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial

Jalal et al., Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21, NCT04867226
May 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization time 24% Improvement Relative Risk Colchicine  Jalal et al.  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 80 patients in Iraq (May - June 2021) Shorter hospitalization with colchicine (p=0.009) c19early.org Jalal et al., Indian J. Rheumatology, May 2022 Favorscolchicine Favorscontrol 0 0.5 1 1.5 2+
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020, now with p = 0.00000031 from 56 studies.
Lower risk for mortality, ICU, hospitalization, and recovery.
No treatment is 100% effective. Protocols combine treatments.
5,300+ studies for 116 treatments. c19early.org
Open label RCT of colchicine showing improved recovery with treatment. Only the abstract is currently available. Colchicine 0.5mg bid for 14 days.
This study is excluded in the after exclusion results of meta analysis: minimal details provided.
hospitalization time, 24.1% lower, relative time 0.76, p = 0.009, treatment 36, control 44.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jalal et al., 5 May 2022, Randomized Controlled Trial, Iraq, peer-reviewed, 3 authors, study period 8 May, 2021 - 18 June, 2021, trial NCT04867226 (history).
This PaperColchicineAll
DOI record: { "DOI": "10.4103/injr.injr_264_21", "ISSN": [ "0973-3698" ], "URL": "http://dx.doi.org/10.4103/injr.injr_264_21", "alternative-id": [ "344591" ], "author": [ { "affiliation": [], "family": "Jalal", "given": "AryanMohamadfatih", "sequence": "first" }, { "affiliation": [], "family": "Aref", "given": "SheelanFaroz", "sequence": "additional" }, { "affiliation": [], "family": "Albustany", "given": "DashtyAbbas", "sequence": "additional" } ], "container-title": "Indian Journal of Rheumatology", "container-title-short": "Indian J Rheumatol", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 5, 3 ] ], "date-time": "2022-05-03T03:21:24Z", "timestamp": 1651548084000 }, "deposited": { "date-parts": [ [ 2022, 5, 3 ] ], "date-time": "2022-05-03T03:22:20Z", "timestamp": 1651548140000 }, "indexed": { "date-parts": [ [ 2022, 5, 4 ] ], "date-time": "2022-05-04T13:15:53Z", "timestamp": 1651670153419 }, "is-referenced-by-count": 0, "issue": "0", "issued": { "date-parts": [ [ 2022 ] ] }, "journal-issue": { "issue": "0", "published-print": { "date-parts": [ [ 2022 ] ] } }, "language": "en", "member": "2581", "original-title": [], "page": "0", "prefix": "10.4103", "published": { "date-parts": [ [ 2022 ] ] }, "published-print": { "date-parts": [ [ 2022 ] ] }, "publisher": "Medknow", "reference-count": 20, "references-count": 20, "relation": {}, "resource": { "primary": { "URL": "http://www.indianjrheumatol.com/preprintarticle.asp?id=344591;type=0" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Rheumatology" ], "subtitle": [], "title": "Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial", "type": "journal-article", "volume": "0" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit